Insulin detemir biosimilar (Tonghua Dongbao Pharmaceutical)

地特胰岛素生物类似药(通化东宝)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInsulin detemir biosimilar (Tonghua Dongbao Pharmaceutical)
Drug Alias Name地特胰岛素生物仿制药(通化东宝)
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeA10AE05
Related LinksN/A